These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 19141144)

  • 21. Retinal ganglion cells, glaucoma and neuroprotection.
    Lipton SA
    Prog Brain Res; 2001; 131():712-8. PubMed ID: 11420983
    [No Abstract]   [Full Text] [Related]  

  • 22. [Retinal ganglion cells death in glaucoma--mechanism and potential treatment. Part II].
    Rokicki W; Dorecka M; Romaniuk W
    Klin Oczna; 2007; 109(7-9):353-5. PubMed ID: 18260297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Neuroprotection in glaucoma. What is the current status?].
    Haefliger IO; Pellanda N; Fleischhauer JC; Gekkieva M; Flammer J
    Ophthalmologe; 2001 Jun; 98(6):564-7. PubMed ID: 11450482
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey.
    Hare W; WoldeMussie E; Lai R; Ton H; Ruiz G; Feldmann B; Wijono M; Chun T; Wheeler L
    Surv Ophthalmol; 2001 May; 45 Suppl 3():S284-9; discussion S295-6. PubMed ID: 11377450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experimental glutamatergic excitotoxicity in rabbit retinal ganglion cells: block by memantine.
    Hare WA; Wheeler L
    Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2940-8. PubMed ID: 19136701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroprotection in glaucoma.
    Tamm ER; Grehn F; Pfeiffer N
    Cell Tissue Res; 2013 Aug; 353(2):201-3. PubMed ID: 23812823
    [No Abstract]   [Full Text] [Related]  

  • 27. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection.
    Nucci C; Bari M; Spanò A; Corasaniti M; Bagetta G; Maccarrone M; Morrone LA
    Prog Brain Res; 2008; 173():451-64. PubMed ID: 18929127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection.
    Russo R; Cavaliere F; Rombolà L; Gliozzi M; Cerulli A; Nucci C; Fazzi E; Bagetta G; Corasaniti MT; Morrone LA
    Prog Brain Res; 2008; 173():575-82. PubMed ID: 18929135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retinal ganglion cell death in glaucoma: mechanisms and neuroprotective strategies.
    Kuehn MH; Fingert JH; Kwon YH
    Ophthalmol Clin North Am; 2005 Sep; 18(3):383-95, vi. PubMed ID: 16054996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Neuroprotection in glaucoma].
    Kuprjanowicz L; Karczewicz D
    Ann Acad Med Stetin; 2007; 53 Suppl 1():22-9. PubMed ID: 19425476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage.
    Lipton SA
    Surv Ophthalmol; 2003 Apr; 48 Suppl 1():S38-46. PubMed ID: 12852433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotective effect of nipradilol [3,4-dihydro-8-(2-hydroxy-3-isopropylamino)-propoxy-3-nitroxy-2H-1-benzopyran] in a rat model of optic nerve degeneration.
    Karim MZ; Sawada A; Mizuno K; Kawakami H; Ishida K; Yamamoto T
    J Glaucoma; 2009 Jan; 18(1):26-31. PubMed ID: 19142131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glaucoma: an open-window to neurodegeneration and neuroprotection. Preface.
    Nucci C; Osbornec NN; Bagetta G; Cerulli L
    Prog Brain Res; 2008; 173():xi. PubMed ID: 18929096
    [No Abstract]   [Full Text] [Related]  

  • 34. Glaucoma: neuroprotection with NAD-based therapeutic interventions.
    Chiarugi A
    Trends Pharmacol Sci; 2023 Dec; 44(12):869-879. PubMed ID: 37880000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secondary retinal ganglion cell death and the neuroprotective effects of the calcium channel blocker lomerizine.
    Fitzgerald M; Payne SC; Bartlett CA; Evill L; Harvey AR; Dunlop SA
    Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5456-62. PubMed ID: 19474405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation.
    Schwartz M; London A
    Prog Brain Res; 2008; 173():375-84. PubMed ID: 18929122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroprotection for glaucoma: Requirements for clinical translation.
    Levin LA; Crowe ME; Quigley HA;
    Exp Eye Res; 2017 Apr; 157():34-37. PubMed ID: 27955999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How to keep injured CNS neurons viable--strategies for neuroprotection and gene transfer to retinal ganglion cells.
    Isenmann S; Schmeer C; Kretz A
    Mol Cell Neurosci; 2004 May; 26(1):1-16. PubMed ID: 15121174
    [No Abstract]   [Full Text] [Related]  

  • 39. Retinal ganglion cell death in glaucoma: Exploring the role of neuroinflammation.
    Russo R; Varano GP; Adornetto A; Nucci C; Corasaniti MT; Bagetta G; Morrone LA
    Eur J Pharmacol; 2016 Sep; 787():134-42. PubMed ID: 27044433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bio-tactics for neuroprotection of retinal ganglion cells in the treatment of glaucoma.
    Yadav KS; Sharma S; Londhe VY
    Life Sci; 2020 Feb; 243():117303. PubMed ID: 31953158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.